We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Daiichi Sankyo Company Ltd (PK) | USOTC:DSNKY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.14 | -0.48% | 28.85 | 28.79 | 28.85 | 28.97 | 28.10 | 28.10 | 217,400 | 18:25:55 |
From Jan 2023 to Jan 2025
By Anthony O. Goriainoff
AstraZeneca said Monday that its datopotamab deruxtecan treatment showed positive results in patients with advanced non-small cell lung cancer in a clinical Phase 3 trial.
The London-listed pharmaceutical giant said the first Phase 3 results showed a statistically-significant improvement in progression-free survival versus standard chemotherapy in patients with locally advanced or metastatic non-small cell lung cancer treated with at least one prior therapy.
The company said datopotamab deruxtecan's safety profile is consistent with previous clinical trials and that no new safety signals identified.
"These first Phase 3 trial results from the datopotamab deruxtecan clinical program provide compelling evidence for the potential role this... antibody drug conjugate can play in treating patients with lung cancer," the company said.
Datopotamab deruxtecan is being jointly developed by AstraZeneca and Daiichi Sankyo.
Write to Anthony O. Goriainoff at anthony.orunagoriainoff@dowjones.com
(END) Dow Jones Newswires
July 03, 2023 02:35 ET (06:35 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Daiichi Sankyo (PK) Chart |
1 Month Daiichi Sankyo (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
